Copper dyshomoeostasis in Parkinson's disease: Implications for pathogenesis and indications for novel therapeutics

Clinical Science

Volumn 130, Issue 8, 2016, Pages 565-574

  Davies, Katherine M ^a,b   Mercer, Julian F B ^c   Chen, Nicholas ^a   Double, Kay L ^d  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c DEAKIN UNIVERSITY   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Brain; Copper; Neurodegeneration; Parkinson's disease; Therapy

Indexed keywords

ALPHA SYNUCLEIN; ANTIPARKINSON AGENT; CERULOPLASMIN; CLIOQUINOL; COPPER; DIACETYLBIS(4 METHYLTHIOSEMICARBAZONE); NEUROPROTECTIVE AGENT; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BRAIN LEVEL; CELL DEATH; COPPER HOMOEOSTASIS; COPPER METABOLISM; HOMEOSTASIS; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; META ANALYSIS (TOPIC); NERVE CELL; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; ANIMAL; BRAIN; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY;

ALPHA-SYNUCLEIN; ANIMALS; ANTIPARKINSON AGENTS; BRAIN; COPPER; HOMEOSTASIS; HUMANS; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 84973563260     PISSN: 01435221     EISSN: 14708736     Source Type: Journal    
DOI: 10.1042/CS20150153     Document Type: Review

References (111)

1. Double, K.L., Reyes, S., Werry, E.L. and Halliday, G.M. (2010) Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions? Progress Neurobiol. 92, 316-329
2. Barnham, K.J. and Bush, A.I. (2008) Metals in Alzheimer's and Parkinson's diseases. Curr. Opin. Chem. Biol. 12, 222-228
3. Ward, R.J., Dexter, D.T. and Crichton, R.R. (2012) Chelating agents for neurodegenerative diseases. Curr. Med. Chem. 19, 2760-2772
4. Sutachan, J.J., Casas, Z., Albarracin, S.L., Stab, 2nd, B.R., Samudio, I., Gonzalez, J., Morales, L. and Barreto, G.E. (2012) Cellular and molecular mechanisms of antioxidants in Parkinson's disease. Nutr. Neurosci. 15, 120-126
5. Bandmann, O., Weiss, K.H. and Kaler, S.G. (2015) Wilson's disease and other neurological copper disorders. Lancet Neurol. 14, 103-113
6. Zlatic, C.O., Mao, Y., Ryan, T.M., Mok, Y.F., Roberts, B.R., Howlett, G.J. and Griffin, M.D. (2015) Fluphenazine.HCl and epigallocatechin gallate modulate the rate of formation and structural properties of apolipoprotein C-II Amyloid Fibrils. Biochemistry 54, 3831-3838
7. Davies, K.M., Hare, D.J., Cottam, V., Chen, N., Hilgers, L., Halliday, G., Mercer, J.F. and Double, K.L. (2013) Localization of copper and copper transporters in the human brain. Metallomics 5, 43-51
8. Dexter, D.T., Carayon, A., Javoy-Agid, F., Agid, Y., Wells, F.R., Daniel, S.E., Lees, A.J., Jenner, P. and Marsden, C.D. (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114 (Pt 4), 1953-1975
9. Bohic, S., Murphy, K., Paulus, W., Cloetens, P., Salome, M., Susini, J. and Double, K. (2008) Intracellular chemical imaging of the developmental phases of human neuromelanin using synchrotron X-ray microspectroscopy. Anal. Chem. 80, 9557-9566
10. Lutsenko, S., Gupta, A., Burkhead, J.L. and Zuzel, V. (2008) Cellular multitasking: the dual role of human Cu-ATPases in cofactor delivery and intracellular copper balance. Arch. Biochem. Biophys. 476, 22-32
11. Brewer, G.J. (2008) The risks of free copper in the body and the development of useful anticopper drugs. Curr. Opin. Clin. Nutr. Metab. Care 11, 727-732
12. Bauerly, K.A., Kelleher, S.L. and Lonnerdal, B. (2004) Functional and molecular responses of suckling rat pups and human intestinal Caco-2 cells to copper treatment. J. Nutr. Biochem. 15, 155-162
13. Kuo, Y.M., Gybina, A.A., Pyatskowit, J.W., Gitschier, J. and Prohaska, J.R. (2006) Copper transport protein (Ctr1) levels in mice are tissue specific and dependent on copper status. J. Nutr. 136, 21-26
14. Nevitt, T., Ohrvik, H. and Thiele, D.J. (2012) Charting the travels of copper in eukaryotes from yeast to mammals. Biochim. Biophys. Acta 1823, 1580-1593
15. Ohgami, R.S., Campagna, D.R., McDonald, A. and Fleming, M.D. (2006) The Steap proteins are metalloreductases. Blood 108, 1388-1394
16. Kelly, E.J. and Palmiter, R.D. (1996) A murine model of Menkes disease reveals a physiological function of metallothionein. Nat. Genet. 13, 219-222
17. Klomp, L.W. and Gitlin, J.D. (1996) Expression of the ceruloplasmin gene in the human retina and brain: implications for a pathogenic model in aceruloplasminemia. Hum. Mol. Genet. 5, 1989-1996
18. Yoshida, K., Furihata, K., Takeda, S., Nakamura, A., Yamamoto, K., Morita, H., Hiyamuta, S., Ikeda, S., Shimizu, N. and Yanagisawa, N. (1995) A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nat. Genet. 9, 267-272
19. Harris, Z.L., Takahashi, Y., Miyajima, H., Serizawa, M., MacGillivray, R.T. and Gitlin, J.D. (1995) Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc. Natl. Acad. Sci. U.S.A. 92, 2539-2543
20. Culotta, V.C., Klomp, L.W., Strain, J., Casareno, R.L., Krems, B. and Gitlin, J.D. (1997) The copper chaperone for superoxide dismutase. J. Biol. Chem. 272, 23469-23472
21. Beers, J., Glerum, D.M. and Tzagoloff, A. (1997) Purification, characterization, and localization of yeast Cox17p, a mitochondrial copper shuttle. J. Biol. Chem. 272, 33191-33196
22. Cobine, P.A., Pierrel, F., Bestwick, M.L. and Winge, D.R. (2006) Mitochondrial matrix copper complex used in metallation of cytochrome oxidase and superoxide dismutase. J. Biol. Chem. 281, 36552-36559
23. Cobine, P.A., Ojeda, L.D., Rigby, K.M. and Winge, D.R. (2004) Yeast contain a non-proteinaceous pool of copper in the mitochondrial matrix. J. Biol. Chem. 279, 14447-14455
24. Maxfield, A.B., Heaton, D.N. and Winge, D.R. (2004) Cox17 is functional when tethered to the mitochondrial inner membrane. J. Biol. Chem. 279, 5072-5080
25. Lee, J., Prohaska, J.R. and Thiele, D.J. (2001) Essential role for mammalian copper transporter Ctr1 in copper homeostasis and embryonic development. Proc. Natl. Acad. Sci. U.S.A. 98, 6842-6847
26. Takahashi, Y., Kako, K., Kashiwabara, S., Takehara, A., Inada, Y., Arai, H., Nakada, K., Kodama, H., Hayashi, J., Baba, T. and Munekata, E. (2002) Mammalian copper chaperone Cox17p has an essential role in activation of cytochrome C oxidase and embryonic development. Mol. Cell Biol. 22, 7614-7621
27. Oswald, C., Krause-Buchholz, U. and Rodel, G. (2009) Knockdown of human COX17 affects assembly and supramolecular organization of cytochrome c oxidase. J. Mol. Biol. 389, 470-479
28. Leary, S.C., Kaufman, B.A., Pellecchia, G., Guercin, G.H., Mattman, A., Jaksch, M. and Shoubridge, E.A. (2004) Human SCO1 and SCO2 have independent, cooperative functions in copper delivery to cytochrome c oxidase. Hum. Mol. Genet. 13, 1839-1848
29. Rothstein, J.D., Dykes-Hoberg, M., Corson, L.B., Becker, M., Cleveland, D.W., Price, D.L., Culotta, V.C. and Wong, P.C. (1999) The copper chaperone CCS is abundant in neurons and astrocytes in human and rodent brain. J. Neurochem. 72, 422-429
30. Kim, H., Son, H.Y., Bailey, S.M. and Lee, J. (2009) Deletion of hepatic Ctr1 reveals its function in copper acquisition and compensatory mechanisms for copper homeostasis. Am. J. Physiol. Gastrointest. Liver Physiol. 296, G356-G364
31. Lee, J., Petris, M.J. and Thiele, D.J. (2002) Characterization of mouse embryonic cells deficient in the ctr1 high affinity copper transporter. Identification of a Ctr1-independent copper transport system. J. Biol. Chem. 277, 40253-40259
32. Ip, V., Liu, J.J., Mercer, J.F. and McKeage, M.J. (2010) Differential expression of ATP7A, ATP7B and CTR1 in adult rat dorsal root ganglion tissue. Mol. Pain 6, 53
33. Mercer, J.F., Livingston, J., Hall, B., Paynter, J.A., Begy, C., Chandrasekharappa, S., Lockhart, P., Grimes, A., Bhave, M., Siemieniak, D. et al. (1993) Isolation of a partial candidate gene for Menkes disease by positional cloning. Nat. Genet. 3, 20-25
34. Gouider-Khouja, N. (2009) Wilson's disease. Parkinsonism Relat. Disord. 15(Suppl 3), S126-S129
35. Capo, C.R., Arciello, M., Squitti, R., Cassetta, E., Rossini, P.M., Calabrese, L. and Rossi, L. (2008) Features of ceruloplasmin in the cerebrospinal fluid of Alzheimer's disease patients. Biometals 21, 367-372
36. Holtzman, N.A. and Gaumnitz, B.M. (1970) Studies on the rate of release and turnover of ceruloplasmin and apoceruloplasmin in rat plasma. J. Biol. Chem. 245, 2354-2358
37. Gaetke, L.M. and Chow, C.K. (2003) Copper toxicity, oxidative stress, and antioxidant nutrients. Toxicology 189, 147-163
38. Valko, M., Morris, H. and Cronin, M.T. (2005) Metals, toxicity and oxidative stress. Curr. Med. Chem. 12, 1161-1208
39. Litwin, T., Gromadzka, G., Szpak, G.M., Jablonka-Salach, K., Bulska, E. and Czlonkowska, A. (2013) Brain metal accumulation in Wilson's disease. J. Neurol. Sci. 329, 55-58
40. Gray, L.W., Peng, F., Molloy, S.A., Pendyala, V.S., Muchenditsi, A., Muzik, O., Lee, J., Kaplan, J.H. and Lutsenko, S. (2012) Urinary copper elevation in a mouse model of Wilson's disease is a regulated process to specifically decrease the hepatic copper load. PloS One 7, e38327
41. Kim, B.E., Turski, M.L., Nose, Y., Casad, M., Rockman, H.A. and Thiele, D.J. (2010) Cardiac copper deficiency activates a systemic signaling mechanism that communicates with the copper acquisition and storage organs. Cell Metab. 11, 353-363
42. Campanella, G., Carrieri, P., Romito, D. and Pasqual-Marsettin, E. (1973) Iron, transferrin, copper and ceruloplasmin of the serum and cerebrospinal fluid in extrapyramidal diseases and primary myopathies. Study in basic conditions and in Parkinsonism after treatment with dopaminergic agents (L-dopa, L-dopa + RO 4-4602, amantadine). Acta Neurol. 28, 1-34
43. Jimenez-Jimenez, F.J., Fernandez-Calle, P., Martinez-Vanaclocha, M., Herrero, E., Molina, J.A., Vazquez, A. and Codoceo, R. (1992) Serum levels of zinc and copper in patients with Parkinson's disease. J. Neurol. Sci. 112, 30-33
44. Jimenez-Jimenez, F.J., Molina, J.A., Aguilar, M.V., Meseguer, I., Mateos-Vega, C.J., Gonzalez-Munoz, M.J., de Bustos, F., Martinez-Salio, A., Orti-Pareja, M., Zurdo, M. and Martinez-Para, M.C. (1998) Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease. J. Neural. Transm. 105, 497-505
45. Pall, H.S., Williams, A.C., Blake, D.R., Lunec, J., Gutteridge, J.M., Hall, M. and Taylor, A. (1987) Raised cerebrospinal-fluid copper concentration in Parkinson's disease. Lancet 2, 238-241
46. Torsdottir, G., Kristinsson, J., Sveinbjornsdottir, S., Snaedal, J. and Johannesson, T. (1999) Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease. Pharmacol. Toxicol. 85, 239-243
47. Arnal, N., Cristalli, D.O., de Alaniz, M.J. and Marra, C.A. (2010) Clinical utility of copper, ceruloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives. Brain Res. 1319, 118-130
48. Mariani, S., Ventriglia, M., Simonelli, I., Donno, S., Bucossi, S., Vernieri, F., Melgari, J.M., Pasqualetti, P., Rossini, P.M. and Squitti, R. (2013) Fe and Cu do not differ in Parkinson's disease: a replication study plus meta-analysis. Neurobiol. Aging 34, 632-633
49. Gazzaniga, G.C., Ferraro, B., Camerlingo, M., Casto, L., Viscardi, M. and Mamoli, A. (1992) A case control study of CSF copper, iron and manganese in Parkinson disease. Ital. J. Neurol. Sci. 13, 239-243
50. Takahashi, S., Takahashi, J., Osawa, N., Abe, T., Yonezawa, H., Sera, K. and Tohgi, H. (1994) Trace elements analysis of serum and cerebrospinal fluid with PIXE -effect of age and changes in parkinsonian patients. Nippon Ronen Igakkai Zasshi 31, 865-871
51. Loeffler, D.A., DeMaggio, A.J., Juneau, P.L., Brickman, C.M., Mashour, G.A., Finkelman, J.H., Pomara, N. and LeWitt, P.A. (1994) Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease. Alzheimer Dis. Assoc. Disord. 8, 190-197
52. Davies, K.M., Bohic, S., Carmona, A., Ortega, R., Cottam, V., Hare, D.J., Finberg, J.P., Reyes, S., Halliday, G.M., Mercer, J.F. and Double, K.L. (2014) Copper pathology in vulnerable brain regions in Parkinson's disease. Neurobiol. Aging 35, 858-866
53. Dexter, D.T., Wells, F.R., Lees, A.J., Agid, F., Agid, Y., Jenner, P. and Marsden, C.D. (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52, 1830-1836
54. Loeffler, D.A., LeWitt, P.A., Juneau, P.L., Sima, A.A., Nguyen, H.U., DeMaggio, A.J., Brickman, C.M., Brewer, G.J., Dick, R.D., Troyer, M.D. and Kanaley, L. (1996) Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders. Brain Res. 738, 265-274
55. Ayton, S., Lei, P., Duce, J.A., Wong, B.X., Sedjahtera, A., Adlard, P.A., Bush, A.I. and Finkelstein, D.I. (2013) Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. Ann. Neurol. 73, 554-559
56. Popescu, B.F., Robinson, C.A., Rajput, A., Rajput, A.H., Harder, S.L. and Nichol, H. (2009) Iron, copper, and zinc distribution of the cerebellum. Cerebellum 8, 74-79
57. Uitti, R.J., Rajput, A.H., Rozdilsky, B., Bickis, M., Wollin, T. and Yuen, W.K. (1989) Regional metal concentrations in Parkinson's disease, other chronic neurological diseases, and control brains. Can. J. Neurol. Sci. 16, 310-314
58. Ayton, S., Lei, P., Duce, J.A., Wong, B.X., Sedjahtera, A., Adlard, P.A., Bush, A.I. and Finkelstein, D.I. (2012) Ceruloplasmin dysfunction and therapeutic potential for parkinson disease. Ann. Neurol. 73, 554-559
59. Wypijewska, A., Galazka-Friedman, J., Bauminger, E.R., Wszolek, Z.K., Schweitzer, K.J., Dickson, D.W., Jaklewicz, A., Elbaum, D. and Friedman, A. (2010) Iron and reactive oxygen species activity in parkinsonian substantia nigra. Parkinsonism Relat. Disord. 16, 329-333
60. Zlatic, S., Comstra, H.S., Gokhale, A., Petris, M.J. and Faundez, V. (2015) Molecular basis of neurodegeneration and neurodevelopmental defects in Menkes disease. Neurobiol. Dis. 81, 154-161
61. Miotto, M.C., Rodriguez, E.E., Valiente-Gabioud, A.A., Torres-Monserrat, V., Binolfi, A., Quintanar, L., Zweckstetter, M., Griesinger, C. and Fernandez, C.O. (2014) Site-specific copper-catalyzed oxidation of alpha-synuclein: tightening the link between metal binding and protein oxidative damage in Parkinson's disease. Inorg. Chem. 53, 4350-4358
62. Binolfi, A., Rodriguez, E.E., Valensin, D., D'Amelio, N., Ippoliti, E., Obal, G., Duran, R., Magistrato, A., Pritsch, O., Zweckstetter, M. et al. (2010) Bioinorganic chemistry of Parkinson's disease: structural determinants for the copper-mediated amyloid formation of alpha-synuclein. Inorg. Chem. 49, 10668-10679
63. Wright, J.A., Wang, X. and Brown, D.R. (2009) Unique copper-induced oligomers mediate alpha-synuclein toxicity. FASEB J. 23, 2384-2393
64. Santner, A. and Uversky, V.N. (2010) Metalloproteomics and metal toxicology of alpha-synuclein. Metallomics 2, 378-392
65. Rose, F., Hodak, M. and Bernholc, J. (2011) Mechanism of copper(II)-induced misfolding of Parkinson's disease protein. Sci. Rep. 1, 11
66. Halliday, G.M., Ophof, A., Broe, M., Jensen, P.H., Kettle, E., Fedorow, H., Cartwright, M.I., Griffiths, F.M., Shepherd, C.E. and Double, K.L. (2005) Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain 128, 2654-2664
67. Tavassoly, O., Nokhrin, S., Dmitriev, O.Y. and Lee, J.S. (2014) Cu(II) and dopamine bind to alpha-synuclein and cause large conformational changes. FEBS J. 281, 2738-2753
68. Ha, Y., Yang, A., Lee, S., Kim, K., Liew, H., Lee, S.H., Lee, J.E., Lee, H.I., Suh, Y.H., Park, H.S. and Churchill, D.G. (2014) Dopamine and Cu+/2+ can induce oligomerization of alpha-synuclein in the absence of oxygen: two types of oligomerization mechanisms for alpha-synuclein and related cell toxicity studies. J. Neurosci. Res. 92, 359-368
69. Wang, X., Moualla, D., Wright, J.A. and Brown, D.R. (2010) Copper binding regulates intracellular alpha-synuclein localisation, aggregation and toxicity. J. Neurochem. 113, 704-714
70. Wilhelm, B.G., Mandad, S., Truckenbrodt, S., Krohnert, K., Schafer, C., Rammner, B., Koo, S.J., Classen, G.A., Krauss, M., Haucke, V. et al. (2014) Composition of isolated synaptic boutons reveals the amounts of vesicle trafficking proteins. Science 344, 1023-1028
71. Moriarty, G.M., Minetti, C.A., Remeta, D.P. and Baum, J. (2014) A revised picture of the Cu(II)-alpha-synuclein complex: the role of N-terminal acetylation. Biochemistry 53, 2815-2817
72. Miotto, M.C., Valiente-Gabioud, A.A., Rossetti, G., Zweckstetter, M., Carloni, P., Selenko, P., Griesinger, C., Binolfi, A. and Fernandez, C.O. (2015) Copper binding to the N-terminally acetylated, naturally occurring form of alpha-synuclein induces local helical folding. J. Am. Chem. Soc. 137, 6444-6447
73. Lutsenko, S., Bhattacharjee, A. and Hubbard, A.L. (2010) Copper handling machinery of the brain. Metallomics 2, 596-608
74. Miller, D.S. and O'Dell, B.L. (1987) Milk and casein-based diets for the study of brain catecholamines in copper-deficient rats. J. Nutr. 117, 1890-1897
75. Prohaska, J.R. and Wells, W.W. (1975) Copper deficiency in the developing rat brain: evidence for abnormal mitochondria. J. Neurochem. 25, 221-228
76. Yajima, K. and Suzuki, K. (1979) Neuronal degeneration in the brain of the brindled mouse. II. Ultrastructure of neuronal inclusions in the cerebral cortex. Acta Neuropathol. 48, 133-137
77. Prohaska, J.R. and Smith, T.L. (1982) Effect of dietary or genetic copper deficiency on brain catecholamines, trace metals and enzymes in mice and rats. J. Nutr. 112, 1706-1717
78. Rossi, L., Marchese, E., Lombardo, M.F., Rotilio, G. and Ciriolo, M.R. (2001) Increased susceptibility of copper-deficient neuroblastoma cells to oxidative stress-mediated apoptosis. Free Radic. Biol. Med. 30, 1177-1187
79. Lombardo, M.F., Ciriolo, M.R., Rotilio, G. and Rossi, L. (2003) Prolonged copper depletion induces expression of antioxidants and triggers apoptosis in SH-SY5Y neuroblastoma cells. Cell. Mol. Life Sci. 60, 1733-1743
80. Valentine, J.S., Doucette, P.A. and Zittin Potter, S. (2005) Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis. Annu. Rev. Biochem. 74, 563-593
81. Girotto, S., Cendron, L., Bisaglia, M., Tessari, I., Mammi, S., Zanotti, G. and Bubacco, L. (2014) DJ-1 is a copper chaperone acting on SOD1 activation. J. Biol. Chem. 289, 10887-10899
82. Polazzi, E., Mengoni, I., Caprini, M., Pena-Altamira, E., Kurtys, E. and Monti, B. (2013) Copper-zinc superoxide dismutase (SOD1) is released by microglial cells and confers neuroprotection against 6-OHDA neurotoxicity. Neuro-Signals 21, 112-128
83. Torsdottir, G., Sveinbjornsdottir, S., Kristinsson, J., Snaedal, J. and Johannesson, T. (2006) Ceruloplasmin and superoxide dismutase (SOD1) in Parkinson's disease: a follow-up study. J. Neurol. Sci. 241, 53-58
84. Boll, M.C., Alcaraz-Zubeldia, M., Montes, S. and Rios, C. (2008) Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochem. Res. 33, 1717-1723
85. Alcaraz-Zubeldia, M., Rojas, P., Boll, C. and Rios, C. (2001) Neuroprotective effect of acute and chronic administration of copper (II) sulfate against MPP+ neurotoxicity in mice. Neurochem. Res. 26, 59-64
86. Rubio-Osornio, M., Montes, S., Perez-Severiano, F., Aguilera, P., Floriano-Sanchez, E., Monroy-Noyola, A., Rubio, C. and Rios, C. (2009) Copper reduces striatal protein nitration and tyrosine hydroxylase inactivation induced by MPP+ in rats. Neurochem. Int. 54, 447-451
87. Przedborski, S., Kostic, V., Jackson-Lewis, V., Naini, A.B., Simonetti, S., Fahn, S., Carlson, E., Epstein, C.J. and Cadet, J.L. (1992) Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci. 12, 1658-1667
88. Miller, D.B., Reinhard, Jr, J.F., Daniels, A.J. and O'Callaghan, J.P. (1991) Diethyldithiocarbamate potentiates the neurotoxicity of in vivo 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and of in vitro 1-methyl-4-phenylpyridinium. J. Neurochem. 57, 541-549
89. Furukawa, Y. and O'Halloran, T.V. (2006) Posttranslational modifications in Cu,Zn-superoxide dismutase and mutations associated with amyotrophic lateral sclerosis. Antioxid. Redox Signal. 8, 847-867
90. Lamb, A.L., Torres, A.S., O'Halloran, T.V. and Rosenzweig, A.C. (2001) Heterodimeric structure of superoxide dismutase in complex with its metallochaperone. Nat. Struct. Biol. 8, 751-755
91. Schmidt, P.J., Rae, T.D., Pufahl, R.A., Hamma, T., Strain, J., O'Halloran, T.V. and Culotta, V.C. (1999) Multiple protein domains contribute to the action of the copper chaperone for superoxide dismutase. J. Biol. Chem. 274, 23719-23725
92. Wang, Z., Liu, J., Chen, S., Wang, Y., Cao, L., Zhang, Y., Kang, W., Li, H., Gui, Y., Chen, S. and Ding, J. (2011) DJ-1 modulates the expression of Cu/Zn-superoxide dismutase-1 through the Erk1/2-Elk1 pathway in neuroprotection. Ann. Neurol. 70, 591-599
93. Bandopadhyay, R., Kingsbury, A.E., Cookson, M.R., Reid, A.R., Evans, I.M., Hope, A.D., Pittman, A.M., Lashley, T., Canet-Aviles, R., Miller, D.W. et al. (2004) The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain 127, 420-430
94. McCarthy, A.M. (2004) Prana Biotechnology, Limited: metal attenuation in the treatment of neurodegenerative disease. Chem. Biol. 11, 1473-1474
95. Litwin, T. and Czlonkowska, A. (2013) Wilson disease -factors affecting clinical presentation. Neurol. Neurochir. Pol. 47, 161-169
96. Lewis, J., Laforest, R., Buettner, T., Song, S., Fujibayashi, Y., Connett, J. and Welch, M. (2001) Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): an agent for radiotherapy. Proc. Natl. Acad. Sci. U.S.A. 98, 1206-1211
97. Hung, L.W., Villemagne, V.L., Cheng, L., Sherratt, N.A., Ayton, S., White, A.R., Crouch, P.J., Lim, S., Leong, S.L., Wilkins, S. et al. (2012) The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease. J. Exp. Med. 209, 837-854
98. Bica, L., Liddell, J.R., Donnelly, P.S., Duncan, C., Caragounis, A., Volitakis, I., Paterson, B.M., Cappai, R., Grubman, A., Camakaris, J. et al. (2014) Neuroprotective copper bis(thiosemicarbazonato) complexes promote neurite elongation. PLoS One 9, e90070
99. Ikawa, M., Okazawa, H., Kudo, T., Kuriyama, M., Fujibayashi, Y. and Yoneda, M. (2011) Evaluation of striatal oxidative stress in patients with Parkinson's disease using [62Cu]ATSM PET. Nucl. Med. Biol. 38, 945-951
100. Ritchie, C.W., Bush, A.I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.X., Tammer, A. et al. (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 60, 1685-1691
101. Cahoon, L. (2009) The curious case of clioquinol. Nat. Med. 15, 356-359
102. Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C.L., Targum, S., Bush, A.I., Murdoch, R. et al. (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 7, 779-786
103. Faux, N.G., Ritchie, C.W., Gunn, A., Rembach, A., Tsatsanis, A., Bedo, J., Harrison, J., Lannfelt, L., Blennow, K., Zetterberg, H. et al. (2010) PBT2 rapidly improves cognition in Alzheimer's disease: additional phase II analyses. J. Alzheimers Dis. 20, 509-516
104. Price, K.A., Filiz, G., Caragounis, A., Du, T., Laughton, K.M., Masters, C.L., Sharples, R.A., Hill, A.F., Li, Q.X., Donnelly, P.S. et al. (2008) Activation of epidermal growth factor receptor by metal-ligand complexes decreases levels of extracellular amyloid beta peptide. Int. J. Biochem. Cell Biol. 40, 1901-1917
105. White, A.R., Du, T., Laughton, K.M., Volitakis, I., Sharples, R.A., Xilinas, M.E., Hoke, D.E., Holsinger, R.M., Evin, G., Cherny, R.A. et al. (2006) Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J. Biol. Chem. 281, 17670-17680
106. Crouch, P.J., Savva, M.S., Hung, L.W., Donnelly, P.S., Mot, A.I., Parker, S.J., Greenough, M.A., Volitakis, I., Adlard, P.A., Cherny, R.A. et al. (2011) The Alzheimer's therapeutic PBT2 promotes amyloid-beta degradation and GSK3 phosphorylation via a metal chaperone activity. J. Neurochem. 119, 220-230
107. Huntington Study Group Reach2HD Investigators (2015) Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 14, 39-47
108. Wilkins, S., Masters, C.L., Bush, A.I., Cherny, R.A. and Finkelstein, D.I. (2009) Clioquinol protects against cell death in Parkinson's disease models in vivo and in vitro. Basal Ganglia IX 431-442
109. Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J.Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M.F. et al. (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37, 899-909
110. Osherovich, L. (2012) Buddy system for orphan disease. SciBX 5, 1020
111. Finkelstein, D.I., George, J.L., Adlard, P.A., Ayton, S., Hung, L.W., Sedjahtera, A., Volitakis, I., Bray, L., Gunawan, L., Kok, G. et al. (2013) PBT434, a novel 8-hydroxyquinazolinone, preserves nigro-striatal circuitry, improves motor performance and inhibits alpha syncuclein accumulation in animal models of Parkinson's disease by modulation of iron homeostasis. Movement Disorders, Abstract Supplement, Abstracts of the 17th International Congress of Parkinson's Disease and Movement Disorders, Sydney, Australia, 16-20 June 2013, 28, S369